These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 8887480

  • 1. Mucosal and systemic immune responses to measles virus haemagglutinin in mice immunized with a recombinant vaccinia virus.
    Etchart N, Wild F, Kaiserlian D.
    J Gen Virol; 1996 Oct; 77 ( Pt 10)():2471-8. PubMed ID: 8887480
    [Abstract] [Full Text] [Related]

  • 2. Class I-restricted CTL induction by mucosal immunization with naked DNA encoding measles virus haemagglutinin.
    Etchart N, Buckland R, Liu MA, Wild TF, Kaiserlian D.
    J Gen Virol; 1997 Jul; 78 ( Pt 7)():1577-80. PubMed ID: 9225032
    [Abstract] [Full Text] [Related]

  • 3. Cholera toxin B stimulates systemic neutralizing antibodies after intranasal co-immunization with measles virus.
    Muller CP, Beauverger P, Schneider F, Jung G, Brons NH.
    J Gen Virol; 1995 Jun; 76 ( Pt 6)():1371-80. PubMed ID: 7782766
    [Abstract] [Full Text] [Related]

  • 4. Mucosal and systemic immune responses induced after oral delivery of vaccinia virus recombinants.
    Gherardi MM, Esteban M.
    Vaccine; 1999 Mar 05; 17(9-10):1074-83. PubMed ID: 10195617
    [Abstract] [Full Text] [Related]

  • 5. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin.
    Elson CO, Ealding W.
    J Immunol; 1984 Jun 05; 132(6):2736-41. PubMed ID: 6233359
    [Abstract] [Full Text] [Related]

  • 6. [Intranasal priming with HIV DNA vaccine and systemic boosting with recombinant vaccinia induce vigorous immune responses: experiment with mice].
    Huang XG, Xu JQ, Ren L, Qiu C, Zhang N, Liu LX, Wan YM, Peng H, Shao YM.
    Zhonghua Yi Xue Za Zhi; 2006 Nov 28; 86(44):3109-13. PubMed ID: 17313761
    [Abstract] [Full Text] [Related]

  • 7. Mucosal adenovirus-vectored vaccine for measles.
    Lobanova LM, Baig TT, Tikoo SK, Zakhartchouk AN.
    Vaccine; 2010 Nov 10; 28(48):7613-9. PubMed ID: 20887832
    [Abstract] [Full Text] [Related]

  • 8. Construction of vaccinia virus recombinants expressing several measles virus proteins and analysis of their efficacy in vaccination of mice.
    Wild TF, Bernard A, Spehner D, Drillien R.
    J Gen Virol; 1992 Feb 10; 73 ( Pt 2)():359-67. PubMed ID: 1538193
    [Abstract] [Full Text] [Related]

  • 9. Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response.
    Coupar BE, Andrew ME, Both GW, Boyle DB.
    Eur J Immunol; 1986 Dec 10; 16(12):1479-87. PubMed ID: 3493144
    [Abstract] [Full Text] [Related]

  • 10. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.
    Virology; 2008 Oct 25; 380(2):412-20. PubMed ID: 18786689
    [Abstract] [Full Text] [Related]

  • 11. Intranasal immunization with recombinant Vaccinia virus Tiantan harboring Zaire Ebola virus gp elicited systemic and mucosal neutralizing antibody in mice.
    Xie L, Zai J, Yi K, Li Y.
    Vaccine; 2019 May 31; 37(25):3335-3342. PubMed ID: 31076161
    [Abstract] [Full Text] [Related]

  • 12. Measles virus hemagglutinin induces an Ld-restricted CD8+ cytotoxic T lymphocyte response to two specific epitopes.
    Beauverger P, Buckland R, Wild F.
    Virology; 1994 Apr 31; 200(1):281-3. PubMed ID: 7510439
    [Abstract] [Full Text] [Related]

  • 13. Characterization of antibody and cytotoxic T lymphocyte responses to human influenza virus H3 haemagglutinin expressed from the haemagglutinin locus of vaccinia virus.
    Itamura S, Iinuma H, Shida H, Morikawa Y, Nerome K, Oya A.
    J Gen Virol; 1990 Dec 31; 71 ( Pt 12)():2859-65. PubMed ID: 2273387
    [Abstract] [Full Text] [Related]

  • 14. Oral tolerance revisited: prior oral tolerization abrogates cholera toxin-induced mucosal IgA responses.
    Kato H, Fujihashi K, Kato R, Yuki Y, McGhee JR.
    J Immunol; 2001 Mar 01; 166(5):3114-21. PubMed ID: 11207263
    [Abstract] [Full Text] [Related]

  • 15. Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant.
    Jackson RJ, Fujihashi K, Xu-Amano J, Kiyono H, Elson CO, McGhee JR.
    Infect Immun; 1993 Oct 01; 61(10):4272-9. PubMed ID: 8406816
    [Abstract] [Full Text] [Related]

  • 16. IgA isotype restriction in the mucosal but not in the extramucosal immune response after oral immunizations with cholera toxin or cholera B subunit.
    Lycke N, Lindholm L, Holmgren J.
    Int Arch Allergy Appl Immunol; 1983 Oct 01; 72(2):119-27. PubMed ID: 6874106
    [Abstract] [Full Text] [Related]

  • 17. Oral administration of cholera toxin-Sendai virus conjugate potentiates gut and respiratory immunity against Sendai virus.
    Liang XP, Lamm ME, Nedrud JG.
    J Immunol; 1988 Sep 01; 141(5):1495-501. PubMed ID: 2842395
    [Abstract] [Full Text] [Related]

  • 18. Analysis of the contribution of CTL epitopes in the immunobiology of morbillivirus infection.
    Beauverger P, Cardoso AI, Daviet L, Buckland R, Wild TF.
    Virology; 1996 May 01; 219(1):133-9. PubMed ID: 8623522
    [Abstract] [Full Text] [Related]

  • 19. Combined oral/nasal immunization protects mice from Sendai virus infection.
    Nedrud JG, Liang XP, Hague N, Lamm ME.
    J Immunol; 1987 Nov 15; 139(10):3484-92. PubMed ID: 2824609
    [Abstract] [Full Text] [Related]

  • 20. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
    Isaka M, Zhao Y, Nobusawa E, Nakajima S, Nakajima K, Yasuda Y, Matsui H, Hasegawa T, Maeyama J, Morokuma K, Ohkuma K, Tochikubo K.
    Microbiol Immunol; 2008 Feb 15; 52(2):55-63. PubMed ID: 18380802
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.